Systematic review: Impact of stem cells-based therapy, and platelet-rich plasma in hair loss and telogen effluvium related to COVID-19

background: the incidence of hair loss (HL) and telogen effluvium (TE) in COVID-19 patients has been reported in several studies. objectives: evaluate both the increased incidence of HL and TE in COVID-19 and the effectiveness of platelet-rich plasma (PRP), adipose-derived mesenchymal stem cells (AD-MSCs), and human follicle stem cells (HFSCs) in these patients. methods: the protocol was developed by the preferred reporting for Items for systematic reviews and meta-analyses-protocols (PRISMA-P) guidelines. a multistep search of pubmed, medline embase, clinicaltrials. gov, scopus, and cochrane databases has been performed to identify papers focusing on HL and TE COVID-19 related, and papers focusing on AD-MSCs, HFSC, and PRP use. results: Of the 404 articles initially identified focusing on HL and TE, 44 were related to COVID-19, and finally, only 6 were analyzed. on the other way, 331 articles focusing on AD-MSCs, HFSC, and PRP were initially identified. Of these, only 6 articles PRP (n = 3), AD-MSCs, and HFSCs (n = 3) have been analyzed. conclusion: collected data confirmed both an increased incidence of HL and TE in COVID-19 patients, preliminarily, the related effectiveness of AD-MSCs, HFSCs, and PRP without major side effects.